Table 4 Objective response rate (ORR) and disease control rate (DCR) by pretreatment serum levels of hepatocyte growth factor (HGF) and epiregulin (EREG) when the appropriate cutoff values were evaluated by ROC curve analysis

From: Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer

  

Pretreatment HGF level

Pretreatment EREG level

  

(cut-off value: 1393.55 pg ml−1)

(cutoff value: 1412.65 pg ml−1)

Response

Total patients

High ( N =47)

Low ( N =56)

P-value

High ( N =55)

Low ( N =48)

P -value

PR

34 (33.0%)

15 (31.9%)

19 (33.9%)

 

13 (23.6%)

21 (43.8%)

 

SD

37 (35.9%)

12 (25.5%)

25 (44.7%)

 

18 (32.8%)

19 (39.5%)

 

PD

32 (31.1%)

20 (42.6%)

12 (21.4%)

 

24 (43.6%)

8 (16.7%)

 

ORR (95% CI)

33.0% (24.1–43.0)

31.9% (19.1–47.1)

33.9% (21.8–47.8)

0.829

23.6% (13.2–37.0)

43.8% (29.3–58.8)

0.030

DCR (95% CI)

68.9% (59.1–77.7)

57.4 % (42.2–71.7)

78.6% (65.6–88.4)

0.021

56.4% (42.3–69.7)

83.3% (69.8–92.5)

0.003

  1. Abbreviations: CI=confidence interval; PD=progressive disease; PR=partial response; ROC=receiver operating characteristics; SD=table disease.
  2. Cutoff values were decided so that it became a DCR best. ORR and DCR in KRAS wild-type patients are shown. Bold values mean statistically significant difference (P-value <0.05).
Back to article page